红斑狼疮新疗法有望惠及中国百万患者

第一财经
Yesterday

系统性红斑狼疮(SLE)作为一种自身免疫性疾病,目前尚无法治愈。长期以来,针对该疾病的创新疗法也备受关注。  近日,阿斯利康公司一款治疗系统性红斑狼疮的生物制剂阿伏利尤单抗(anifrolumab)的三期临床试验结果显示,针对亚洲成年中重度系统性红斑狼疮患者,与安慰剂组相比,在降低疾病活动度和减少口服糖皮质激素用量方面均显示出统计学和临床意义上的改善。  阿斯利康援引数据称,全球约有超过340万的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10